Literature DB >> 24909741

Increased interleukin 33 in patients with neuro-Behcet's disease: correlation with MCP-1 and IP-10 chemokines.

Kamel Hamzaoui1, Afshin Borhani-Haghighi2, Wajih Kaabachi1, Agnes Hamzaoui3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24909741      PMCID： PMC4220833          DOI： 10.1038/cmi.2014.31

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  10 in total

1.  Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases.

Authors:  Güher Saruhan-Direskeneli; Sibel P Yentür; Gülşen Akman-Demir; Nihal Işik; Piraye Serdaroğlu
Journal:  J Neuroimmunol       Date:  2003-12       Impact factor: 3.478

2.  Induction of IL-33 expression and activity in central nervous system glia.

Authors:  Chad A Hudson; George P Christophi; Ross C Gruber; Joel R Wilmore; David A Lawrence; Paul T Massa
Journal:  J Leukoc Biol       Date:  2008-06-13       Impact factor: 4.962

Review 3.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

4.  The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription.

Authors:  Shafaqat Ali; Antje Mohs; Meike Thomas; Jan Klare; Ralf Ross; Michael Lienhard Schmitz; Michael Uwe Martin
Journal:  J Immunol       Date:  2011-07-06       Impact factor: 5.422

5.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.

Authors:  Jochen Schmitz; Alexander Owyang; Elizabeth Oldham; Yaoli Song; Erin Murphy; Terril K McClanahan; Gerard Zurawski; Mehrdad Moshrefi; Jinzhong Qin; Xiaoxia Li; Daniel M Gorman; J Fernando Bazan; Robert A Kastelein
Journal:  Immunity       Date:  2005-11       Impact factor: 31.745

6.  Magnetic resonance imaging findings and outcome of neuro-Behçet's disease: the predictive factors.

Authors:  Siamak Farahangiz; Sirous Sarhadi; Anahid Safari; Afshin Borhani-Haghighi
Journal:  Int J Rheum Dis       Date:  2012-10-27       Impact factor: 2.454

Review 7.  Disease-associated functions of IL-33: the new kid in the IL-1 family.

Authors:  Foo Y Liew; Nick I Pitman; Iain B McInnes
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

Review 8.  Treatment of neuro-Behçet's disease: an update.

Authors:  Afshin Borhani Haghighi
Journal:  Expert Rev Neurother       Date:  2009-04       Impact factor: 4.618

9.  Serum IL-33 levels and skin mRNA expression in Behçet's disease.

Authors:  Kamel Hamzaoui; Wajih Kaabachi; Bessima Fazaa; Leith Zakraoui; Ilhem Mili-Boussen; Faycal Haj-Sassi
Journal:  Clin Exp Rheumatol       Date:  2013-03-04       Impact factor: 4.473

Review 10.  Chemokines in acute respiratory distress syndrome.

Authors:  Padmam Puneet; Shabbir Moochhala; Madhav Bhatia
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-01       Impact factor: 5.464
  10 in total
  9 in total

1.  Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet's disease.

Authors:  Abdullah Kursat Cingu; Fatih Mehmet Turkcu; Serdar Aktas; Alparslan Sahin; Orhan Ayyildiz
Journal:  Int Ophthalmol       Date:  2020-07-29       Impact factor: 2.031

2.  Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency.

Authors:  Xinmei Xie; Lin Wang; Wenliang Yang; Ruishuang Yu; Qingli Li; Xiaobin Pang
Journal:  Invest New Drugs       Date:  2015-05-09       Impact factor: 3.850

Review 3.  Knitting the Threads of Silk through Time: Behçet's Disease-Past, Present, and Future.

Authors:  Fahd Adeeb; Austin G Stack; Alexander D Fraser
Journal:  Int J Rheumatol       Date:  2017-09-10

Review 4.  Expression and Function of IL-33/ST2 Axis in the Central Nervous System Under Normal and Diseased Conditions.

Authors:  Karen Fairlie-Clarke; Mark Barbour; Chelsey Wilson; Shehla U Hridi; Debbie Allan; Hui-Rong Jiang
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

5.  IL-33/IL-31 Axis in Immune-Mediated and Allergic Diseases.

Authors:  Giuseppe Murdaca; Monica Greco; Alessandro Tonacci; Simone Negrini; Matteo Borro; Francesco Puppo; Sebastiano Gangemi
Journal:  Int J Mol Sci       Date:  2019-11-22       Impact factor: 5.923

6.  Increased T-bet/GATA-3 and ROR-γt /Foxp3 Ratios in Cerebrospinal Fluid as Potential Criteria for Definite Neuro-Behçet's Disease.

Authors:  Meriam Belghith; Olfa Maghrebi; Aroua Cherif; Khadija Bahrini; Zakaria Saied; Samir Belal; Samia Ben Sassi; Mohamed-Ridha Barbouche; Mariem Kchaou
Journal:  J Clin Med       Date:  2022-07-29       Impact factor: 4.964

Review 7.  Therapeutic Opportunities of Interleukin-33 in the Central Nervous System.

Authors:  Yun Sun; Yankai Wen; Luxi Wang; Liang Wen; Wendong You; Shuang Wei; Lin Mao; Hao Wang; Zuobing Chen; Xiaofeng Yang
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

8.  CXCL10/CXCR3 axis is associated with disease activity and the development of mucocutaneous lesions in patients with Behçet's disease.

Authors:  Sang Jin Lee; Shin Eui Kang; Eun Ha Kang; Byoong Yong Choi; Katherine Masek-Hammerman; Jameel Syed; Yutian Zhan; Kathleen Neff-Phillips; Jin Kyun Park; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

Review 9.  The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies.

Authors:  Hamidreza Zalpoor; Abdullatif Akbari; Azam Samei; Razieh Forghaniesfidvajani; Monireh Kamali; Azadeh Afzalnia; Shirin Manshouri; Fatemeh Heidari; Majid Pornour; Majid Khoshmirsafa; Hossein Aazami; Farhad Seif
Journal:  Cell Mol Biol Lett       Date:  2022-02-02       Impact factor: 5.787
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.